| Chemical & Physical Properties | |
|---|---|
| CAS Number | 127294-70-6 |
| Catalog No. | 2A-9009297 |
| Chinese Name | 巴洛沙星 |
| Synonyms | q35; MFCD00864925; baloxin; BALOFLOXACIN EXTRA PURE; Balofloxacin |
| Molecular Formula | C20H24FN3O4.2H2O |
| Molecular Weight | 389.42 |
| Purity | ≥98 (HPLC) |
| Density | 1.4±0.1 g/cm3 |
| Boiling Point | 608.3±55.0 °C at 760 mmHg |
| Melting Point | 137ºC |
| Appearance | powder |
| Storage Condition | 2-8°C |
| Packaging | 25kg/drum |
| Application | Balofloxacin is a quinolone antibiotic that can inhibit bacterial DNA synthesis by interfering with DNA gyrase. |
| HTC | 2933990090 |
| SMILES | CNC1CCCN(C1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F |
| InChI | 1S/C20H24FN3O4/c1-22-11-4-3-7-23(9-11)17-15(21)8-13-16(19(17)28-2)24(12-5-6-12)10-14(18(13)25)20(26)27/h8,10-12,22H,3-7,9H2,1-2H3,(H,26,27) |
| InChI Key | MGQLHRYJBWGORO-UHFFFAOYSA-N |
| NACRES Code | NA.41 |
| UNSPSC | 51101500 |
| MSDS | msds/9297_1_127294_70_6.pdf |
| Bioactivity | Balofloxacin is quinolone antibiotic, inhibiting the synthesis of bacterial DNA by interference with the enqyme DNA gyrase.Target: Antibacterial; DNA gyrase.Balofloxacin, an orally active fluoroquinolone antibiotic, has been developed by Choongwae Pharma in Korea, for the treatment of urinary tract infection (UTI). Chugai and Ciba were developing balofloxacin for respiratory tract infections (RTI) but discontinued development in 1995 due to changes in Chugai's R&D focus and a lack of efficacy of the drug. Following phase II trials, Choongwae bought the rights to develop balofloxacin in Korea from Chugai. Phase III trials for UTI were completed in early 2001. Balofloxacin was approved by the Korean FDA in December 2001 for UTI. In March 2002, phase II trials were underway for RTI. Related Catalog Signaling Pathways >> Anti-infection >> Bacterial Research Areas >> Infection References [1]. Alksne L. Balofloxacin Choongwae. Curr Opin Investig Drugs. 2003 Feb;4(2):224-9. Chemical & Physical Properties Density 1.4±0.1 g/cm3 Boiling Point 608.3±55.0 °C at 760 mmHg Melting Point 137ºC Molecular Formula C20H24FN3O4 Molecular Weight 389.42 Flash Point 321.7±31.5 °C PSA 60.69000 LogP 1.24 Vapour Pressure 0.0±1.8 mmHg at 25°C Index of Refraction 1.639 InChIKey MGQLHRYJBWGORO-UHFFFAOYSA-N SMILES CNC1CCCN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2OC)C1 Storage condition 2-8°C |
| Use of | Balofloxacin is quinolone antibiotic, inhibiting the synthesis of bacterial DNA by interference with the enqyme DNA gyrase.Target: Antibacterial; DNA gyrase.Balofloxacin, an orally active fluoroquinolone antibiotic, has been developed by Choongwae Pharma in Korea, for the treatment of urinary tract infection (UTI). Chugai and Ciba were developing balofloxacin for respiratory tract infections (RTI) but discontinued development in 1995 due to changes in Chugai's R&D focus and a lack of efficacy of the drug. Following phase II trials, Choongwae bought the rights to develop balofloxacin in Korea from Chugai. Phase III trials for UTI were completed in early 2001. Balofloxacin was approved by the Korean FDA in December 2001 for UTI. In March 2002, phase II trials were underway for RTI. Properties Articles25 Name Balofloxacin Synonym More Synonyms Balofloxacin Biological Activity Description Balofloxacin is quinolone antibiotic, inhibiting the synthesis of bacterial DNA by interference with the enqyme DNA gyrase.Target: Antibacterial; DNA gyrase.Balofloxacin, an orally active fluoroquinolone antibiotic, has been developed by Choongwae Pharma in Korea, for the treatment of urinary tract infection (UTI). Chugai and Ciba were developing balofloxacin for respiratory tract infections (RTI) but discontinued development in 1995 due to changes in Chugai's R&D focus and a lack of efficacy of the drug. Following phase II trials, Choongwae bought the rights to develop balofloxacin in Korea from Chugai. Phase III trials for UTI were completed in early 2001. Balofloxacin was approved by the Korean FDA in December 2001 for UTI. In March 2002, phase II trials were underway for RTI. Related Catalog Signaling Pathways >> Anti-infection >> Bacterial Research Areas >> Infection References [1]. Alksne L. Balofloxacin Choongwae. Curr Opin Investig Drugs. 2003 Feb;4(2):224-9. Chemical & Physical Properties Molecular Formula C20H24FN3O4 PSA 60.69000 Index of Refraction 1.639 InChIKey MGQLHRYJBWGORO-UHFFFAOYSA-N |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Product name: Summary 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
| Related Products in API & Advanced Intermediates | ||
|---|---|---|
| Atomoxetine | 83015-26-3 | 2A-9009258 |
| Atorvastatin | 134523-00-5 | 2A-9009259 |
| Atorvastatin calcium | 134523-03-8 | 2A-9009260 |
| Azathioprine | 446-86-6 | 2A-9009278 |
| Azithromycin | 83905-01-5 | 2A-9009286 |
| Benazepril | 86541-75-5 | 2A-9009323 |
| Benazeprilat | 86541-78-8 | 2A-9009325 |
| beta-Lumicolchicine | 2A-300463 | 2A-9009380 |
| Betamethasone butyrate propionate | 5534-02-1 | 2A-9009381 |
| Betamethasone Dipropionate | 5593-20-4 | 2A-9009382 |
| Browse all API & Advanced Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS